Company
Headquarters: Cincinnati, OH, United States
Founded: 1992
Employees: 4,500
CEO: Dr. August James Troendle M.D.
$10.81 Billion
USD as of Jan. 1, 2025
Company | Market Cap (USD) |
---|---|
Thermo Fisher Scientific | $219.88 B |
Danaher | $177.43 B |
Siemens Healthineers AG | $59.19 B |
Agilent Technologies, Inc. | $43.57 B |
Lonza Group Ltd | $41.66 B |
Company | Market Cap (USD) |
---|---|
Lilly | $689.42 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $487.54 B |
Johnson & Johnson | $353.05 B |
AbbVie | $301.60 B |
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Last Financial Reports Date | Sept. 30, 2024 |
Revenue TTM | $2.07 B |
EBITDA | $439.7 M |
Gross Profit TTM | $1.39 B |
Profit Margin | 17.66% |
Operating Margin | 21.05% |
Quarterly Revenue Growth | 8.30% |
Medpace Holdings, Inc. has the following listings and related stock indices.
Stock: NASDAQ: MEDP wb_incandescent
Stock: BMV: MEDP wb_incandescent
Stock: FSX: 01P wb_incandescent
Support services for pharmaceutical and medical device
Dr. August J. Troendle, President and CEO